ClinicalTrials.gg
Not yet recruitingNCT06363175PREMIEREUpdated Apr 15, 2024

PREMs In Vascular SurgERy Enhancement Study

An observational study in Vascular Diseases, Patient Empowerment and Patient Satisfaction, sponsored by Cardiff and Vale University Health Board. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by Cardiff and Vale University Health Board · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
330
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Vascular Diseases with a site in United Kingdom — 12 open to participants now, 17 under way, 2 of them phase 3. Vascular Diseases · United Kingdom.

Planned enrollment
8th of 19
330 · median 200
Started
2024
with 2 others
Observational
19 of 62
6 open now
Primary completion
2025-08
later than 5 of 16 live
Registered
58th of 62
by date

Among the 62 studies in Vascular Diseases with a site in United Kingdom, this one is the 8th largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2024, is one of 19 observational ones, reaches primary completion later than 5 of the 16 other live ones, and was the 58th registered.

Vascular Diseases

694 studies on the registry are indexed under Vascular Diseases; 127 are open to participants now.

Browse Vascular Diseases studies →

Open to participants now

12 of the 62 studies in Vascular Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 95 Vascular Diseases studies recruiting now, 59 (62%) set no upper age limit and 13 (14%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Vascular Diseases with a site in United Kingdom, or all of them as a file.
02

Study summary

THE PROBLEM:

Patient Reported Experience Measures (PREMs) ask patients about their healthcare service experience. It gives them a voice to share their views. PREMs allow healthcare providers (HCPs) to see where care is good, and where they could improve. Vascular surgery is a surgical speciality looking after people's blood vessels (arteries and veins).

There is no PREM available for vascular patients. The research team want to create a PREM for this patient group.

WHY IT IS IMPORTANT:

A PREM allows HCPs to record and understand patients' experiences of their treatment. It gives patients a way to provide feedback on their healthcare experience. PREMs can help HCPs make changes to patients' care, identifying areas of good practice and areas for improvement. The Welsh Government is keen to support the use of PREMs.

AIMS:

To develop a PREM specific to vascular surgery patients.

RESEARCH PLAN:

The research team will summarise the literature about PREMs in surgery. The research team will then run focus groups and interviews with patients and staff to create a 'draft' PREM for vascular patients in Wales. The 'draft' PREM will be translated into Welsh.

In the second phase, a larger number of vascular patients (100-300 depending on how long the 'draft' PREM is) from hospitals across Wales will complete the questionnaire. Statistical tests will look at the results to see if the questionnaire works well to capture patients' experiences. Based on these results, small changes will be made to make the 'draft' PREM better. This will make sure the 'final PREM' is ready for widespread use in Wales and beyond.

PATIENT AND PUBLIC INVOLVEMENT:

The patients' experience team at CAVUHB has reviewed our patients' materials. Our research team includes PPI co-applicants (DC and AH). DC a double amputee who has had many vascular operations. DC has experience raising awareness about vascular disease through public forums like the Limbless Association Charity and BBC Radio Wales. AH has issues with her leg due to smoking and had a keyhole operation to help with that. She had some problems after the procedure This is her first time as a PPI representative. DC and AH supported our research design and will be steering group members. Also, our research focuses on giving patients a voice and will include patients across Wales. A diverse group of patients will be involved across all stages of the PREM development.

Read the detailed description

Background: PREMs have emerged as instruments designed to capture patients' experiences of their healthcare journey. No PREMs have been developed or validated to be used among vascular surgery patients specifically.

Objectives: To develop and validate a PREM specific to vascular surgery, assessing the patient's experience and satisfaction with their care and treatment.

Study design and methods: Patient Reported Experience Measures In Vascular Surgery Enhancement Study (PREMIERE) is a multi-site sequential mixed-methods cohort design, incorporating qualitative and quantitative approaches in two phases. The first phase will focus on developing a draft PREM for vascular surgery patients, while the second phase will aim to validate the draft PREM to create a 'final PREM'. Patient inclusion criteria are: (i) age ≥18 ; (ii) have undergone a vascular procedure (iii) experienced an inpatient vascular care within the previous 3 months; (iv) not cognitively impaired; (v) willing and able to provide written consent for participation; (vi) able to communicate in English or Welsh.

Statistical analysis: For the qualitative phase, inductive thematic analysis will be carried out using the non-numerical data analysis for Windows software NVivo . For quantitative data, psychometric tests such as item analysis, internal consistency, construct validity, and principal component analysis with varimax rotation will be used to extract factors. Quantitative data will be analysed using IBM SPSS Statistics (Version 27) software.

Anticipated impact: PREMIERE will contribute to the development of a robust and context-specific PREM for vascular patients. This PREM will provide a valuable tool for assessing and improving the in-patient vascular surgery pathway, including pre-operative, peri-operative, and post-operative phases. Also, the utilization of a robust vascular PREM presents a transformative opportunity to benchmark and enhance the performance of vascular units.

03

Conditions studied

  • Vascular Diseases
  • Patient Empowerment
  • Patient Satisfaction
  • Patient Engagement
  • Surgery

Keywords

  • Patient Reported Experience Measure
  • PREM
  • Vascular surgery
  • Patient centred care
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients undergoing in-patient vascular care, which involves specialized vascular surgery for hospital-admitted individuals, including those recently discharged with conditions like peripheral artery disease. Recruitment will engage patients preoperatively and post-service (within 1-3 months) to minimize bias. The study will target UK's central vascular units for diverse patient demographics. Consistent eligibility criteria will apply to both study phases (development and validation).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have recently (within the last three months) undergone a vascular procedure or intervention under the care of a vascular surgery team in the inpatient setting.
  • Adults aged 18 years or older
  • Not cognitively impaired (as determined by medical reports and/or self-reporting).
  • Willing and able to provide written consent for participation.
  • Able to speak, read and write English or Welsh

Exclusion criteria

Exclusion Criteria:

  • Patients who lack capacity or suffer from cognitive impairment.
  • Patients who are unable to speak, read and write English or Welsh.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
330 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Degree of Validity of the PREM

    Validity: The extent to which a measure assesses what it intends to measure.

    Time frame: Day 0, Day 30

  2. Degree of Reliability of the PREM

    Reliability: The consistency and stability of a measure over time and across different conditions.

    Time frame: Day 0, Day 30

  3. Degree of Responsiveness of the PREM

    Responsiveness: The ability of a measure to detect change over time in the concept being measured.

    Time frame: Day 0, Day 30

  4. Degree of Feasibility of implementing the PREM in clinical practice

    Feasibility: The practicality and suitability of implementing a measure in a specific setting or context.

    Time frame: Day 0, Day 30

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The full dataset is not expected to be made available for secondary research. In accordance with standard measures to prevent statistical disclosure, quantitative data relating to five or fewer individuals will be aggregated or redacted prior to publication. Similarly, full focus group transcripts will not be made available to external individuals or organisations due to the possibility of statistical disclosure from these qualitative data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2024; primary completion for Aug 2025, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2024
First posted
Apr 12, 2024
StartEst.
Jun 1, 2024
Primary completionEst.
Aug 1, 2025
CompletionEst.
Jun 1, 2026
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06363175
Lead sponsor
Cardiff and Vale University Health Board
Collaborators
Welsh Value in Health Centre (WViHC), Centre for Healthcare Evaluation, Device Assessment, and Research (CEDAR)
Responsible party
Sponsor
First posted
Apr 12, 2024
Start date
Jun 1, 2024 (estimated)
Primary completion
Aug 1, 2025 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Apr 15, 2024

Study contacts

Maram Darwish, MD
Contact
maram.darwish@wales.nhs.uk
+447841582039
Rachel Norman
Contact
rachel.norman2@wales.nhs.uk
+442921846126
David C Bosanquet, FRCS
principal investigator · CARDIFF & VALE UNIVERSITY LHB

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion